CD20 × CD3 bispecific antibodies for lymphoma therapy: latest updates from ASCO 2023 annual meeting

Multiple bispecific antibodies (bsAbs) have been approved for cancer immunotherapy. Several CD20 × CD3 bsAbs have demonstrated significant anti-B-cell non-Hodgkin lymphoma (NHL) activity by engaging T cells to target CD20(+) NHL cells in clinical trials. Mosunetuzumab, epcoritamab and glofitamab hav...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Xinyuan, Zhao, Juanjuan, Guo, Xiangqian, Song, Yongping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Correspondence
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10401875/
https://www.ncbi.nlm.nih.gov/pubmed/37537626
http://dx.doi.org/10.1186/s13045-023-01488-4
_version_ 1785084762207027200
author Liu, Xinyuan
Zhao, Juanjuan
Guo, Xiangqian
Song, Yongping
author_facet Liu, Xinyuan
Zhao, Juanjuan
Guo, Xiangqian
Song, Yongping
author_sort Liu, Xinyuan
collection PubMed
description Multiple bispecific antibodies (bsAbs) have been approved for cancer immunotherapy. Several CD20 × CD3 bsAbs have demonstrated significant anti-B-cell non-Hodgkin lymphoma (NHL) activity by engaging T cells to target CD20(+) NHL cells in clinical trials. Mosunetuzumab, epcoritamab and glofitamab have been approved recently for B-cell NHL therapy. In this study, we summarized several latest reports on CD20 × CD3 bsAbs for the therapy of B-cell NHL from the ASCO 2023 annual meeting (ASCO2023).
format Online
Article
Text
id pubmed-10401875
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-104018752023-08-05 CD20 × CD3 bispecific antibodies for lymphoma therapy: latest updates from ASCO 2023 annual meeting Liu, Xinyuan Zhao, Juanjuan Guo, Xiangqian Song, Yongping J Hematol Oncol Correspondence Multiple bispecific antibodies (bsAbs) have been approved for cancer immunotherapy. Several CD20 × CD3 bsAbs have demonstrated significant anti-B-cell non-Hodgkin lymphoma (NHL) activity by engaging T cells to target CD20(+) NHL cells in clinical trials. Mosunetuzumab, epcoritamab and glofitamab have been approved recently for B-cell NHL therapy. In this study, we summarized several latest reports on CD20 × CD3 bsAbs for the therapy of B-cell NHL from the ASCO 2023 annual meeting (ASCO2023). BioMed Central 2023-08-03 /pmc/articles/PMC10401875/ /pubmed/37537626 http://dx.doi.org/10.1186/s13045-023-01488-4 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Correspondence
Liu, Xinyuan
Zhao, Juanjuan
Guo, Xiangqian
Song, Yongping
CD20 × CD3 bispecific antibodies for lymphoma therapy: latest updates from ASCO 2023 annual meeting
title CD20 × CD3 bispecific antibodies for lymphoma therapy: latest updates from ASCO 2023 annual meeting
title_full CD20 × CD3 bispecific antibodies for lymphoma therapy: latest updates from ASCO 2023 annual meeting
title_fullStr CD20 × CD3 bispecific antibodies for lymphoma therapy: latest updates from ASCO 2023 annual meeting
title_full_unstemmed CD20 × CD3 bispecific antibodies for lymphoma therapy: latest updates from ASCO 2023 annual meeting
title_short CD20 × CD3 bispecific antibodies for lymphoma therapy: latest updates from ASCO 2023 annual meeting
title_sort cd20 × cd3 bispecific antibodies for lymphoma therapy: latest updates from asco 2023 annual meeting
topic Correspondence
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10401875/
https://www.ncbi.nlm.nih.gov/pubmed/37537626
http://dx.doi.org/10.1186/s13045-023-01488-4
work_keys_str_mv AT liuxinyuan cd20cd3bispecificantibodiesforlymphomatherapylatestupdatesfromasco2023annualmeeting
AT zhaojuanjuan cd20cd3bispecificantibodiesforlymphomatherapylatestupdatesfromasco2023annualmeeting
AT guoxiangqian cd20cd3bispecificantibodiesforlymphomatherapylatestupdatesfromasco2023annualmeeting
AT songyongping cd20cd3bispecificantibodiesforlymphomatherapylatestupdatesfromasco2023annualmeeting

Ejemplares similares